Purple Biotech Lawsuit Dismissed by Court
Ticker: PPBT · Form: 6-K · Filed: Jun 20, 2024 · CIK: 1614744
Sentiment: bullish
Topics: legal, litigation, dismissal
TL;DR
Court throws out class action lawsuit against Purple Biotech, case closed.
AI Summary
On June 19, 2024, Purple Biotech Ltd. announced that the Tel Aviv District Court (Economic Division) dismissed a lawsuit filed against the company, its executive directors, and certain present and former directors. This lawsuit, filed in February, had sought class action status.
Why It Matters
The dismissal of the class action lawsuit removes a significant legal overhang for Purple Biotech, potentially improving investor confidence and reducing future legal expenses.
Risk Assessment
Risk Level: low — The filing reports the dismissal of a lawsuit, which is a positive development and does not introduce new risks.
Key Players & Entities
- Purple Biotech Ltd. (company) — Registrant
- Tel Aviv District Court (Economic Division) (company) — Court that dismissed the lawsuit
- June 19, 2024 (date) — Date of lawsuit dismissal
- February (date) — Month lawsuit was filed
FAQ
What was the nature of the lawsuit filed against Purple Biotech?
The lawsuit was a motion to approve a lawsuit as a class action, filed against Purple Biotech, its executive directors, and certain present and former directors.
Which court dismissed the lawsuit?
The Tel Aviv District Court (Economic Division) dismissed the lawsuit.
On what date was the lawsuit dismissed?
The lawsuit was dismissed on June 19, 2024.
When was the lawsuit originally filed?
The lawsuit was originally filed in February.
What was the outcome of the court's decision?
The court dismissed the lawsuit and the motion to approve it as a class action.
Filing Stats: 631 words · 3 min read · ~2 pages · Grade level 20 · Accepted 2024-06-20 09:16:45
Key Financial Figures
- $7.8 million — oximately NIS 29 million (approximately $7.8 million). Now, the Court has issued its final
Filing Documents
- ea0208164-6k_purplebio.htm (6-K) — 14KB
- 0001213900-24-054044.txt ( ) — 15KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. June 20, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2